What is the share price of Anthem Biosciences Ltd (ANTHEM) today?
The share price of ANTHEM as on 21st May 2026 is ₹769.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Anthem Biosciences Ltd (ANTHEM) share?
The past returns of Anthem Biosciences Ltd (ANTHEM) share are- Past 1 week: -5.61%
- Past 1 month: 4.28%
- Past 3 months: 12.79%
- Past 6 months: 21.10%
- Past 1 year: 5.31%
- Past 3 years: N/A%
- Past 5 years: 5.31%
What are the peers or stocks similar to Anthem Biosciences Ltd (ANTHEM)?
The peers or stocks similar to Anthem Biosciences Ltd (ANTHEM) include:What is the market cap of Anthem Biosciences Ltd (ANTHEM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Anthem Biosciences Ltd (ANTHEM) is ₹43957.38 Cr as of 21st May 2026.What is the 52 week high and low of Anthem Biosciences Ltd (ANTHEM) share?
The 52-week high of Anthem Biosciences Ltd (ANTHEM) is ₹873.50 and the 52-week low is ₹579.15.What is the PE and PB ratio of Anthem Biosciences Ltd (ANTHEM) stock?
The P/E (price-to-earnings) ratio of Anthem Biosciences Ltd (ANTHEM) is 74.28. The P/B (price-to-book) ratio is 18.24.Which sector does Anthem Biosciences Ltd (ANTHEM) belong to?
Anthem Biosciences Ltd (ANTHEM) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Anthem Biosciences Ltd (ANTHEM) shares?
You can directly buy Anthem Biosciences Ltd (ANTHEM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Anthem Biosciences Ltd
ANTHEM Share Price
NSE₹769.101.46% (-11.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ANTHEM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ANTHEM Performance & Key Metrics
ANTHEM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 74.28 | 18.24 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 43.62 | 6.35 | 0.48% |
100%
Analysts have suggested that investors can buy this stock
from 7 analysts
Price Upside
Earnings Growth
Rev. Growth
ANTHEM Company Profile
Anthem Biosciences Limited is an Indian CRDMO offering integrated drug discovery, development, and manufacturing services for biotech and pharma clients including proteins, antibodies, peptides, and highly potent compounds.
BIOCON
PE Ratio
181.73
181.73
1Y Return
30.14%
30.14%
Buy Reco %
73.33
73.33
SAILIFE
PE Ratio
69.38
69.38
1Y Return
56.05%
56.05%
Buy Reco %
100.00
100.00
ACUTAAS
PE Ratio
66.20
66.20
1Y Return
144.43%
144.43%
Buy Reco %
88.89
88.89
ONESOURCE
PE Ratio
-290.05
-290.05
1Y Return
12.93%
12.93%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-305.78
-305.78
1Y Return
19.05%
19.05%
Buy Reco %
0.00
0.00
ANTHEM Sentiment Analysis
ANTHEM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ANTHEM Stock Summary · February 2026
Anthem Biosciences reported a consolidated revenue of Rs. 1,513 crore for the nine months ending December 31, 2025, driven by strong performance in its CRDMO and specialty ingredients segments, despite facing challenges from a one-time exceptional item related to new Labor Codes. The company anticipates a 20% revenue growth for FY27, bolstered by an expanding customer base in the biotech sector and strategic investments in capacity, including a significant capital expenditure for Unit-4. While management remains optimistic about maintaining EBITDA margins above 40%, concerns about rising employee costs and market uncertainties persist. The focus on biosimilars and peptide development, alongside proactive capacity planning, positions Anthem favorably to capitalize on emerging market opportunities and regulatory improvements.
ANTHEM Stock Growth Drivers
ANTHEM Stock Growth Drivers
7Strong Financial Performance
Anthem Biosciences reported consolidated revenue from operations of Rs. 1,513 crore for the nine months
Positive Market Positioning
Anthem has established itself as a leader in the peptide market through complete backward integration,
ANTHEM Stock Challenges
ANTHEM Stock Challenges
2Slowdown in Product Performance
The company has acknowledged a slowdown in some of its products, attributed to a high
Delayed Revenue Realization
While there has been some revenue generation from newly approved molecules, significant revenue impact is
ANTHEM Forecast
ANTHEM Forecasts
Price
Revenue
Earnings
ANTHEM Share Price Forecast
ANTHEM Share Price Forecast
2026
Current
₹769.10
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹769.10
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ANTHEM Company Revenue Forecast
ANTHEM Company Revenue Forecast
2026
Current
₹2.28
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.28
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ANTHEM Stock EPS (Earnings Per Share) Forecast
ANTHEM Stock EPS (Earnings Per Share) Forecast
2026
Current
₹10.55
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹10.55
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ANTHEM
ANTHEM
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ANTHEM Income Statement
ANTHEM Income Statement
Quarterly Normal View
| Quarter | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 358.05 | 552.80 | 522.18 | 497.26 | 563.02 | 598.26 | 456.68 | 663.14 | ||||||||
Operating & Other expenses | 217.69 | 329.73 | 338.30 | 288.00 | 348.72 | 332.12 | 291.32 | 343.73 | ||||||||
EBITDA | 140.36 | 223.07 | 183.88 | 209.26 | 214.30 | 266.14 | 165.36 | 319.41 | ||||||||
| Depreciation/Amortization | 18.68 | 19.99 | 20.28 | 30.42 | 26.45 | 33.50 | 34.53 | 39.59 | ||||||||
| PBIT | 121.68 | 203.08 | 163.60 | 178.84 | 187.85 | 232.64 | 130.83 | 279.82 | ||||||||
| Interest & Other Items | 3.71 | 3.55 | 2.55 | 0.52 | 1.61 | 3.03 | 0.35 | 1.90 | ||||||||
| PBT | 117.97 | 199.53 | 161.05 | 178.32 | 186.24 | 229.61 | 130.48 | 277.92 | ||||||||
| Taxes & Other Items | 35.60 | 37.60 | 36.72 | 95.69 | 50.46 | 56.17 | 37.66 | 88.16 | ||||||||
| Net Income | 82.37 | 161.93 | 124.33 | 82.63 | 135.78 | 173.44 | 92.82 | 189.76 | ||||||||
| EPS | 1.47 | 2.90 | 2.22 | 1.48 | 2.43 | 3.09 | 1.65 | 3.38 |
ANTHEM Company Updates
FY 2026FY 2026
Investor Presentation
May 19PDF
Feb 5PDF
Nov 8PDF
Aug 13PDF
ANTHEM Stock Peers
ANTHEM Past Performance & Peer Comparison
ANTHEM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Anthem Biosciences Ltd | 74.28 | 18.24 | — |
| Biocon Ltd | 181.73 | 2.53 | 0.09% |
| Sai Life Sciences Ltd | 69.38 | 11.37 | — |
| Acutaas Chemicals Ltd | 66.20 | 17.87 | 0.17% |
ANTHEM Stock Price Comparison
Compare ANTHEM with any stock or ETFCompare ANTHEM with any stock or ETF
ANTHEM
ANTHEM Holdings
ANTHEM Shareholdings
ANTHEM Promoter Holdings Trend
ANTHEM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ANTHEM Institutional Holdings Trend
ANTHEM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ANTHEM Shareholding Pattern
ANTHEM Shareholding Pattern
ANTHEM Shareholding History
ANTHEM Shareholding History
Foreign Institutions
Mutual Funds Invested in ANTHEM
Mutual Funds Invested in ANTHEM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Anthem Biosciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1906% | Percentage of the fund’s portfolio invested in the stock 0.57% | Change in the portfolio weight of the stock over the last 3 months 0.57% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 37/71 (+32) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8779% | Percentage of the fund’s portfolio invested in the stock 4.88% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/44 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6368% | Percentage of the fund’s portfolio invested in the stock 0.92% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 77/123 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing ANTHEM stock
smallcases containing ANTHEM stock
Looks like this stock is not in any smallcase yet.
ANTHEM Events
ANTHEM Events
ANTHEM Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ANTHEM has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ANTHEM Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ANTHEM has not given any dividends in last 5 years
ANTHEM Upcoming Dividends
ANTHEM Upcoming Dividends
Cash Dividend
Ex DateEx DateJun 25, 2026
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 25, 2026
ANTHEM Past Dividends
ANTHEM Past Dividends
No past dividends are available
ANTHEM Stock News & Opinions
ANTHEM Stock News & Opinions
Articles & Videos
Corporate
Anthem Biosciences schedules AGM
Anthem Biosciences announced that the 20th Annual General Meeting(AGM) of the company will be held on 22 July 2026.
22 hours agoCapital Market - Live
Corporate
Board of Anthem Biosciences recommends final dividend
Anthem Biosciences announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 100%) , subject to the approval of the shareholders.
1 day agoCapital Market - Live
Earnings
Anthem Biosciences consolidated net profit rises 129.68% in the March 2026 quarter
Net profit of Anthem Biosciences rose 129.68% to Rs 189.76 crore in the quarter ended March 2026 as against Rs 82.62 crore during the previous quarter ended March 2025. Sales rose 26.44% to Rs 610.94 crore in the quarter ended March 2026 as against Rs 483.20 crore during the previous quarter ended March 2025. For the full year,net profit rose 31.14% to Rs 591.79 crore in the year ended March 2026 as against Rs 451.26 crore during the previous year ended March 2025. Sales rose 15.17% to Rs 2124.33 crore in the year ended March 2026 as against Rs 1844.55 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales610.94483.20 26 2124.331844.55 15 OPM %43.7440.40 -39.2536.37 - PBDT316.53208.73 52 982.70746.24 32 PBT276.94178.31 55 848.63656.87 29 NP189.7682.62 130 591.79451.26 31 Powered by Capital Market - Live
1 day agoCapital Market - Live
Corporate
Anthem Biosciences to hold board meeting
Anthem Biosciences will hold a meeting of the Board of Directors of the Company on 19 May 2026.
1 week agoCapital Market - Live
Corporate
Anthem Biosciences allots 1.03 lakh equity shares under ESOP
Anthem Biosciences has allotted 1,03,800 equity shares under ESOP on 05 February 2026. Consequent to this allotment, the paid-up equity share capital of the Company stand increased from Rs. 1,12,32,20,102/- (consisting of 56,16,10,051 equity shares of face value of Rs. 2 each) to Rs. 1,12,34,27,702/- (consisting of 56,17,13,851 equity shares of face value of Rs. 2 each).Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Anthem Biosciences consolidated net profit declines 25.34% in the December 2025 quarter
Net profit of Anthem Biosciences declined 25.34% to Rs 92.82 crore in the quarter ended December 2025 as against Rs 124.33 crore during the previous quarter ended December 2024. Sales declined 15.00% to Rs 423.15 crore in the quarter ended December 2025 as against Rs 497.81 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales423.15497.81 -15 OPM %37.1532.04 - PBDT190.38181.33 5 PBT155.84161.05 -3 NP92.82124.33 -25 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Anthem Biosciences to announce Quarterly Result
Anthem Biosciences will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Anthem Biosciences consolidated net profit rises 7.10% in the September 2025 quarter
Net profit of Anthem Biosciences rose 7.10% to Rs 173.43 crore in the quarter ended September 2025 as against Rs 161.93 crore during the previous quarter ended September 2024. Sales rose 4.78% to Rs 550.03 crore in the quarter ended September 2025 as against Rs 524.96 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales550.03524.96 5 OPM %39.6237.19 - PBDT263.10219.52 20 PBT229.60199.53 15 NP173.43161.93 7 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Anthem Biosciences to announce Quarterly Result
Anthem Biosciences will hold a meeting of the Board of Directors of the Company on 8 November 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Anthem Biosciences consolidated net profit rises 64.83% in the June 2025 quarter
Net profit of Anthem Biosciences rose 64.83% to Rs 135.79 crore in the quarter ended June 2025 as against Rs 82.38 crore during the previous quarter ended June 2024. Sales rose 59.55% to Rs 540.21 crore in the quarter ended June 2025 as against Rs 338.59 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales540.21338.59 60 OPM %35.4535.71 - PBDT212.69136.65 56 PBT186.25117.98 58 NP135.7982.38 65 Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 24.19%, vs industry avg of 21.41%
Over the last 5 years, market share increased from 7.21% to 8.08%
Over the last 5 years, net income has grown at a yearly rate of 37.23%, vs industry avg of 23.38%